Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
Part of paid clinical trials in Chula Vista, California.
- Sponsor
- Vanda Pharmaceuticals
- Study ID
- NCT07686081
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Ulcerative Colitis (UC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ponesimod — DRUGPonesimod administered orally once daily. Participants are randomized 2:1 to Ponesimod or placebo during a 16-week double-blind period. A 14-day titration is followed by a stable dose daily from Day 15 through end of treatment. Participants may enter a 36-week open-label extension receiving Ponesimod.
- Placebo — DRUGMatching placebo administered orally once daily during a 16-week double-blind period (2:1 randomization). A mock 14-day titration is used to maintain blinding. Participants may enter a 36-week open-label extension receiving Ponesimod.
Study Details
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
Key Dates
- Start date
- Sep 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Apr 30, 2029
- Completion
- Aug 31, 2029
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ponesimod (VSP-128)
- Placebo Comparator: Placebo
Primary Outcome Measure
Clinical Remission at Week 16 [ Time Frame: Week 16 ]
Central Contacts
- Vanda Pharmaceuticals Inc.202-734-3400
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vanda Investigational Site | Chula Vista | California | 91910 | - |
| Vanda Investigational Site | Nashville | Tennessee | 37211 | - |
Find similar trials in Chula Vista, CA
Related Studies
- A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel DiseasePHASE2 · Recruiting · Mirador Therapeutics, Inc. · Birmingham, Alabama
- LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisPHASE2 · Recruiting · Eli Lilly and Company · Phoenix, Arizona
- VR Therapies for IBDNot Yet Recruiting · Brennan Spiegel · Los Angeles, California
- Online Pain Education for Crohn's Disease and Ulcerative ColitisNot Yet Recruiting · Cedars-Sinai Medical Center · Los Angeles, California